Stock Screener ETF Screener

Penny Stock Screener Technical Analysis Screener

Dividend Center Best Dividend Stocks

Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison

Dividend Calculator Dividend Returns Comparison Dividend Calendar

My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors

Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire Arrived EquityMultiple

Follow Us

TOOLS

Top Insiders Stocks

Notification Center

Top Smart Score Stocks

Plans & Pricing

Research Tools

Trending Stocks

Most Visited Websites

Daily Feeds

Daily Analyst Ratings

Daily Insider Trading Tracker

Calendars

Earnings Calendar

Dividend Calendar

Economic Calendar

Market Holidays

Economic Indicators

Economic Indicators Center

Unemployment Rate

Federal Funds Rate

Class Actions

Calculators

Dividend Calculator

Dividend Yield Calculator

Options Profit Calculator

Dollar Cost Averaging

Penny Stock Screener

Technical Analysis Screener

Dividend Center

Best Dividend Stocks

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Enterprise Solutions

Education

How To Use TipRanks

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

TipRanks News Wire

Follow Us

Replimune Group Inc (REPL)

NASDAQ:REPL

US Market

REPL

Replimune Group

Analyst Forecasts

Technical Analysis

RESEARCH TOOLS

Top Analyst Stocks

Top Smart Score Stocks

reports

Holding REPL?

Track your performance easily

Replimune Group (REPL) Stock News & Sentiment

247 Followers

Replimune Group Advances Cancer Treatment with FDA Submission

Company Announcements

Replimune Group Advances Cancer Treatment with FDA Submission

2M ago

Replimune Group’s Q3 2024 Financial Highlights

Company Announcements

Replimune Group’s Q3 2024 Financial Highlights

3M ago

Replimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global Uncertainties

Company Announcements

Replimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global Uncertainties

3M ago

REPL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

REPL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

3M ago

Replimune Group Secures Funding for Cancer Treatment Expansion

Company Announcements

Replimune Group Secures Funding for Cancer Treatment Expansion

8M ago

Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes

Company Announcements

Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes

8M ago

Is REPL a Buy, Before Earnings?

Pre-Earnings

Is REPL a Buy, Before Earnings?

9M ago

More REPL News >

REPL News on the Web

2025-01-23

Replimune price target raised to $21 from $17 at H.C. Wainwright

Yahoo Finance

Neutral

2025-01-22

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

Yahoo Finance

Neutral

2025-01-21

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Yahoo Finance

Neutral

2025-01-08

Replimune Doses First Patient In RP2 Clinical Trials For Uveal Melanoma And HCC

rttnews

Neutral

2024-11-26

Replimune Prices Public Offering Of 6.923 Mln Common Shares At $13/Shr

rttnews

Neutral

2024-11-25

Optimistic Buy Rating for Replimune Group Amid Promising Developments in Melanoma Treatment

TipRanks News

Bullish

2024-11-22

Replimune's stock surges 19% after-hours on FDA BLA submission

Yahoo Finance

Bullish

2024-11-22

Replimune Seeks FDA Approval For RP1 In Advanced Melanoma Under Accelerated Approval Pathway

rttnews

Neutral

News Score - Last 7 Days

Neutral

REPL

Sector Average

Media Buzz

This Week0 articles

Weekly Average0 articles

News Sentiment

This Week50%

Sector Average64%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is REPL’s Media Buzz Sentiment?

Currently, no data Available

What is REPL’s weekly average amount of articles?

Currently, no data Available

What is REPL’s News Sentiment?

50% of articles about REPL were positive this week, compared to its sector average of 64%.

Healthcare Stocks that are Trending in the News

LNTHLantheus

CORTCorcept Therapeutics

INBSIntelligent Bio Solutions

AGLANGLE plc

AKROAkero Therapeutics

Showing the stocks with the most bullish news sentiment over the past week

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing